On 2 December 2020, Shanghai Allist Pharmaceutical Co., Ltd. ("Allist") was officially listed on the Shanghai Stock Exchange STAR market (Stock Code: 688578). As the issuer's lawyer, Llinks has provided legal services for Allist's listing.
Founded in March 2004, Allist is an innovative pharmaceutical company oriented by the global pharmaceutical market demand, focusing on the field of oncology treatment, integrating new drug research and development, industrialization and marketization.
The soon-to-be-approved Iversha® is the third representative of the skin growth factor subject tyrosine kinase inhibitor (EGFR-TKI), which is primarily used to treat skin growth factor subjects (EGFR) positive for sensitive mutations. And EGFR T790M bit mutation positive local late stage or metastasis non-small cell lung cancer (NSCLC), is Allist independently developed and has independent intellectual property rights of the country 1.1 class of new drugs, is currently China's clinically urgently needed new drug products.
